Florence, Italy - 13 May 2016: Myocardial fibrosis could be a future therapeutic target after researchers found it correlated with adverse cardiovascular outcomes in patients with obstructive ...

Citation information: Myocardial Fibrosis in the Pathogenesis, Diagnosis, and Treatment of Hypertrophic Cardiomyopathy, Zeyi Cheng, Miaomiao Qi, Chengyuan Zhang and Yanxia Mao, Cardiovasc.

Myocardial fibrosis, a hallmark of hypertrophic cardiomyopathy, is thought to contribute to sudden cardiac death, ventricular tachyarrhythmias, left ventricular dysfunction, and heart failure. 8 ...

Myocardial fibrosis is an important prognostic marker in the development of adverse cardiovascular events, such as heart failure and death. Skip to content. Menu. Medical Home Life Sciences Home.

August 12, 2010 (Boston, Massachusetts) — Is myocardial fibrosis in hypertrophic cardiomyopathy (HCM) a result of longstanding disease, or can it emerge early in the process, perhaps even as one ...

Key Results. Change in myocardial ECV from baseline to week 52 was positively correlated with change in left ventricular end diastolic volume, indexed for body surface area (r, 0.23; P = .039) and ...

Patients with Duchenne or Becker muscular dystrophy assigned ACE inhibitor therapy had slower progression of myocardial fibrosis compared with patients assigned the usual care, according to new ...

For patients with dilated cardiomyopathy, myocardial fibrosis independently predicts all-cause mortality; and for patients with coronary artery disease and regional wall thinning, ...

These findings were maintained in a model excluding patients with myocardial scar, interim myocardial infarction, and severe aortic stenosis. Myocardial scar was more likely to be seen when patients’ ...

WASHINGTON — Among patients with asymptomatic severe aortic stenosis and myocardial fibrosis, transcatheter or surgical aortic valve replacement did not improve outcomes compared with guideline ...